Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Wanbury Limited ( (IN:WANBURY) ) is now available.
Wanbury Limited’s Board of Directors approved the unaudited financial results for the third quarter and nine months ending December 31, 2024, highlighting the company’s financial performance. Additionally, they announced the issuance of senior, secured, unrated, unlisted, redeemable, and non-convertible debentures totaling Rs. 175 crore from Emerging India Credit Opportunities Fund II on a private placement basis, indicating an effort to raise capital for future projects. Furthermore, the company granted 200,000 stock options to employees under its 2016 ESOP plan, aiming to incentivize and retain talent.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical formulations and active pharmaceutical ingredients. The company is engaged in serving both domestic and international markets, with a commitment to providing quality healthcare solutions.
YTD Price Performance: -27.70%
Average Trading Volume: 22,819
Current Market Cap: 7.55B INR
For an in-depth examination of WANBURY stock, go to TipRanks’ Stock Analysis page.